plpp1  (Proteintech)

Journal: International Journal of Molecular Sciences

Article Title: Z-Ligustilide Combined with Cisplatin Reduces PLPP1-Mediated Phospholipid Synthesis to Impair Cisplatin Resistance in Lung Cancer

doi: 10.3390/ijms242317046

Figure Lengend Snippet: Z-ligustilide+cisplatin reduced the phospholipid contents and upregulated PLPP1 expression. ( A ) Heat map of the differential lipids in A549, A549/DDP cells and A549/DDP cells for Z-ligustilide+cisplatin. ( B ) Pathway enrichment analysis. ( C ) Relative enrichment of each lipid class. *** p < 0.001. ( D ) GSEA analysis of the RNA-seq data. The glycerophospholipid metabolism pathway–targeted genes show significant overlap. ( E ) Heat map for RNA–Seq analysis of significantly differentially expressed genes in A549 cells vs. A549/DDP cells vs. A549/DDP cells treated with Z-ligustilide+cisplatin. Red box represented the target gene. ( F ) Protein level of PLPP1 determined via Western blot.

Article Snippet: The primary antibody for PLPP1 (known as PPAP2A, Cat. No. NBP1-59011; Novus Biologicals, Colorado, USA) was used for immunohistochemical staining, and the dilution ratio of the PLPP1 antibody was 1:200.

Techniques: Expressing, RNA Sequencing, Western Blot

Journal: International Journal of Molecular Sciences

Article Title: Z-Ligustilide Combined with Cisplatin Reduces PLPP1-Mediated Phospholipid Synthesis to Impair Cisplatin Resistance in Lung Cancer

doi: 10.3390/ijms242317046

Figure Lengend Snippet: PLPP1 expression was low and associated with poor prognosis in lung cancer. ( A ) PLPP1 expression was detected in LUAD, LUSC, and corresponding normal tissues. LUAD (num (T) = 483; num (N) = 347). LUSC (num (T) = 486; num (N) = 338). * p < 0.05. ( B ) Representative images of the immunohistochemical staining of PLPP1 in lung cancer samples. Scale bars, 50 μm. −: negative expression; +: lower expression; ++: moderate expression; +++: high expression. The score criteria are described in detail in Materials and Methods. ( C ) The association between the PLPP1 protein expression and overall survival in patients with lung cancer. Low PLPP1 expression (n = 41), high PLPP1 expression (n = 35). * p < 0.05. ( D ) The correlation between PLPP1 expression and overall survival in 1451 lung cancer patients. ( E ) The correlation between PLPP1 expression and overall survival in 116 lung cancer patients administered chemotherapy. ( F ) The correlation between PLPP1 expression and overall survival in 268 lung cancer patients without chemotherapy.

Article Snippet: The primary antibody for PLPP1 (known as PPAP2A, Cat. No. NBP1-59011; Novus Biologicals, Colorado, USA) was used for immunohistochemical staining, and the dilution ratio of the PLPP1 antibody was 1:200.

Techniques: Expressing, Immunohistochemical staining, Staining

Journal: International Journal of Molecular Sciences

Article Title: Z-Ligustilide Combined with Cisplatin Reduces PLPP1-Mediated Phospholipid Synthesis to Impair Cisplatin Resistance in Lung Cancer

doi: 10.3390/ijms242317046

Figure Lengend Snippet: Z-ligustilide+cisplatin induced the reversal of resistance mediated by PLPP1. ( A ) Protein expression of PLPP1 in shCtrl and PLPP1 knockdown A549/DDP and H460/DDP cells, respectively. ( B ) Cell viability was measured in shCtrl and PLPP1 knockdown A549/DDP and H460/DDP cells with or without the Z-ligustilide and cisplatin combination treatment, *** p < 0.001. ( C ) Relative protein expressions in shCtrl and PLPP1 knockdown A549/DDP and H460/DDP cells with or without the Z-ligustilide and cisplatin combination treatment.

Article Snippet: The primary antibody for PLPP1 (known as PPAP2A, Cat. No. NBP1-59011; Novus Biologicals, Colorado, USA) was used for immunohistochemical staining, and the dilution ratio of the PLPP1 antibody was 1:200.

Techniques: Expressing, Knockdown

Journal: International Journal of Molecular Sciences

Article Title: Z-Ligustilide Combined with Cisplatin Reduces PLPP1-Mediated Phospholipid Synthesis to Impair Cisplatin Resistance in Lung Cancer

doi: 10.3390/ijms242317046

Figure Lengend Snippet: Z-ligustilide+cisplatin induced the inactivation of AKT by inhibiting PLPP1-mediated phospholipid synthesis. ( A ) The relative enrichments of each lipid class in shCtrl and PLPP1 knockdown A549/DDP cells with or without the Z-ligustilide and cisplatin combination treatment. ns, not significant, *** p < 0.001. ( B ) Protein expression of p-AKT in shCtrl and PLPP1 knockdown A549/DDP and H460/DDP cells with or without the Z-ligustilide and cisplatin combination treatment. ( C , D ) PI3K kinase activity assay and PIP 3 level measurements in shCtrl and PLPP1 knockdown A549/DDP and H460/DDP cells with or without the Z-ligustilide and cisplatin combination treatment. ns, not significant, ** p < 0.01 and *** p < 0.001.

Article Snippet: The primary antibody for PLPP1 (known as PPAP2A, Cat. No. NBP1-59011; Novus Biologicals, Colorado, USA) was used for immunohistochemical staining, and the dilution ratio of the PLPP1 antibody was 1:200.

Techniques: Knockdown, Expressing, Kinase Assay

Journal: Cell communication and signaling : CCS

Article Title: Metabolic reprogramming and heterogeneity during the decidualization process of endometrial stromal cells.

doi: 10.1186/s12964-024-01763-y

Figure Lengend Snippet: Fig. 4 Differential Expression of Amino Acid Metabolism and Lipid Metabolism-Associated Genes Between Decidua and Stroma. A mRNA expression levels of genes involved in amino acid metabolism and lipid metabolism pathways between secretory endometrium and decidua of early pregnancy examined by RT-qPCR (n = 8 per group). E, secretory endometrium; D, decidua. Data are presented as the mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. B Western blot analysis and quantitation of the protein level of key genes involved in amino acid and lipid metabolism (n = 4 per group). C Representa tive multiplex immunohistochemical images of the protein level of amino acid metabolic genes (GPX1, MGST1, MAOB, GLUL) and lipid metabolic genes (PLPP1, PSAP, DHRS3) in normal decidua (n = 2).

Article Snippet: The tissue slides were then subjected to heat-induced epitope retrieval using Tris-EDTA buffer (C1034, Solarbio, pH = 8.0) for 20 min, then washed with 1xTBST buffer (T1082, Solarbio) and blocked non-specific binding with 30% goat serum for 1 h. Next, the slides were incubated overnight with primary antibodies of two panels, including CK8 (Cat: MABT329, diluted 1:500, Sigma-Aldrich), DHRS3 (Cat: 15393-1-AP, diluted 1:100, Proteintech), PSAP (Cat: 10801-1-AP, diluted 1:100, Proteintech), and PLPP1 (Cat: 160,691, diluted 1:100, ZENBIOSCIENCE); CK8 (Cat: MABT329, diluted 1:500, Sigma-Aldrich), GPX1 (Cat: 381,587, diluted 1:100, ZENBIOSCIENCE), MAOB (Cat: 12602-1-AP, diluted 1:100, Proteintech), MGST1 (Cat: R22577, diluted 1:100, ZENBIOSCIENCE) and GLUL (Cat: 11037-2-AP, diluted 1:100, Proteintech), respectively.

Techniques: Quantitative Proteomics, Expressing, Quantitative RT-PCR, Western Blot, Quantitation Assay, Multiplex Assay, Immunohistochemical staining